文献速递免疫规划传染病防控与疫情报告

意大利新冠疫苗首剂后不同时间间隔的感染、住院和死亡风险

Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021.
PubMed 文献 · Euro Surveill · 2021-01-01

95%CI: 0.21-0.24);住院和死亡风险也分别下降,首剂后36-42天住院风险降低89%(IRR: 0.11;95%CI: 0.09-0.15),死亡风险降低93%(IRR: 0.07;95%CI: 0.04-0.11)。结果支持持续开展疫苗接种活动。

要点

  • 首剂后43-49天感染风险降低78%(IRR 0.22,95%CI 0.21-0.24)。
  • 首剂后36-42天住院风险降低89%(IRR 0.11,95%CI 0.09-0.15)。
  • 首剂后36-42天死亡风险降低93%(IRR 0.07,95%CI 0.04-0.11)。

核心结论

  • 接种首剂新冠疫苗后,SARS-CoV-2感染、住院和死亡风险随时间间隔延长而下降。

主要发现

  • 首剂后43-49天感染风险降低78%(IRR: 0.22;95%CI: 0.21-0.24)。
  • 首剂后36-42天住院风险降低89%(IRR: 0.11;95%CI: 0.09-0.15)。
  • 首剂后36-42天死亡风险降低93%(IRR: 0.07;95%CI: 0.04-0.11)。

临床怎么用

  • 结果支持持续开展疫苗接种活动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0-14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21-0.24) 43-49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09-0.15) and 93% (IRR: 0.07; 95% CI: 0.04-0.11) reductions 36-42 days post-first dose. Our results support ongoing vaccination campaigns.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Mateo-Urdiales A, Spila Alegiani S, Fabiani M, et al. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021. Euro Surveill. 2021. PMID: 34169819. doi:10.2807/1560-7917.ES.2021.26.25.2100507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。